annual meeting program - American Society of Clinical Oncology

Sunday, June 6, 2010
Brd. 55D A phase II clinical trial of a novel combinatorial antitumor immunotherapy for
patients with high-risk resected stage III and metastatic melanoma. (Abstract
#8586)
A. I. Riker, L. C. Alsfeld, M. Harrison, D. Foxworth, Q. Lee, G. R. Rossi, L. Tennant,
W. J. Ramsey, N. N. Vahanian, C. J. Link
Brd. 55E Prognostic value of serum YKL-40 in stage IIB-III melanoma patients
receiving adjuvant interferon therapy. (Abstract #8587)
M. Krogh, I. J. Christensen, M. Bouwhuis, J. S. Johansen, H. Schmidt, J. Hansson,
S. Aamdal, A. Testori, A. M. Eggermont, L. Bastholt, The Nordic Melanoma Group
and EORTC Melanoma Group
Brd. 55F Interleukin-10 as a prognostic factor in patients treated with autologous
melanoma cell vaccine. (Abstract #8588)
A. Mahipal, D. Berd, I. Chervoneva, M. Terai, M. J. Mastrangelo, T. Sato
Brd. 55G Electrochemotherapy with bleomycin: A local treatment with possible
systemic implication. (Abstract #8589)
A. Testori, F. Verrecchia, J. Soteldo, G. Spadola, C. Martinoli, S. Gandini,
C. Passoni, F. Cataldo, A. Di Pietro, P. Ferrucci
Brd. 55H Dual mechanistic function of MDSC subsets in melanoma resistance.
(Abstract #8590)
E. C. Borden, J. Ko Smith, P. A. Rayman, B. Jacobs, J. Ireland, D. Lindner, J. Finke
Brd. 56A Immunohistochemical expression of Dicer in melanoma. (Abstract #8591)
C. Capalbo, F. Passarelli, Z. di Rocco, A. Scoppola, P. Marchetti
Brd. 56B PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic
characteristics of therapy-associated cutaneous neoplasms in a phase I trial.
(Abstract #8592)
M. E. Lacouture, G. A. McArthur, P. B. Chapman, A. Ribas, K. T. Flaherty,
R. J. Lee, K. B. Nolop, K. B. Kim, M. Duvic, J. A. Sosman, Dermatology Working
Group
Brd. 56D Utility of 3-year torso CT and head imaging in asymptomatic patients with
high-risk melanoma. (Abstract #8594)
E. R. DeRose, A. Pleet, V. J. Seery, M. Lee, S. Renzi, R. J. Sullivan, M. B. Atkins
Brd. 56E Comparison of classification systems in melanoma sentinel nodes: An
analysis of 697 patients from a single center. (Abstract #8595)
R. Gutzmer, F. Schenck, I. Satzger
Brd. 56F Prognostic relevance of increased detection of lymphovascular invasion in
primary melanoma using D2-40 and CD34 compared to routine histology.
(Abstract #8596)
F. Darvishian, A. E. Rose, P. J. Christos, T. Tu, R. L. Shapiro, R. S. Berman,
A. C. Pavlick, H. Kamino, M. Mazumdar, I. Osman
Brd. 56G Effect of mutational status on response, PFS, or OS after treatment with IL-2
for metastatic melanoma. (Abstract #8597)
R. W. Joseph, R. J. Sullivan, D. Panka, G. Manoukian, A. Percy, R. Harrell,
R. L. Bassett Jr., M. B. Atkins, P. Hwu, M. A. Davies
227
SUNDAY